Answers are grounded in this paper and cite their sources.
We present the case of a 27 year old woman with widely disseminated metastatic adenocarcinoma of the lung who outlived stage IV diagnosis of NSCLC by more than 4 years. Based on rebiopsy and molecular diagnostics of oncogene dependency, appropriately targeted therapies were successfully employed up to a fifth line oral monotherapy with the ErbB family blocker afatinib for a final 11 months. We stress the importance of rebiopsies, the corresponding selection of targeted therapies, and the observed gain in quality of live even in end stage disease.
No takes yet. Share an insight, caveat, or question.
Stoehlmacher-Williams et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: